
On Saturday, Genmab reported all data from a successful phase II study of drug candidate epcoritamab as a treatment for large B-cell lymphoma (LBCL).
Having taken a closer look at the results, Senior Equity Analyst at Sydbank Søren Løntoft Hansen says Genmab’s drug is well-positioned in relation to a competing candidate, Roche’s glofitamab.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app